brl-28500 and Cellulitis

brl-28500 has been researched along with Cellulitis* in 3 studies

Trials

1 trial(s) available for brl-28500 and Cellulitis

ArticleYear
Timentin versus moxalactam in the treatment of skin and soft tissue infections.
    The American journal of medicine, 1985, Nov-29, Volume: 79, Issue:5B

    Topics: Adult; Aged; Bacteria; Bacterial Infections; Cellulitis; Clavulanic Acids; Drug Combinations; Female; Humans; Male; Middle Aged; Moxalactam; Penicillins; Skin Diseases, Infectious; Ticarcillin

1985

Other Studies

2 other study(ies) available for brl-28500 and Cellulitis

ArticleYear
Ticarcillin/clavulanate for the treatment of female genital tract infections. Efficacy, safety and comparative microbiology.
    The Journal of reproductive medicine, 1990, Volume: 35, Issue:3 Suppl

    In an open study, ticarcillin/clavulanate was used to treat upper genital tract infections in 91 women. The clinical success rate was 92% in outpatient-acquired salpingitis (pelvic inflammatory disease), 50% in salpingitis with tuboovarian abscess, 85% in postpartum endometritis, 87% in endometritis after chorioamnionitis and 90% in postoperative parametritis. The primary adverse reaction was diarrhea, in 10 patients. Among the 129 aerobes isolated, 18 (14%) were beta-lactamase positive, as were 32% (20/63) of the anaerobes.

    Topics: Abortion, Septic; Adult; Bacteria; beta-Lactamase Inhibitors; Cellulitis; Clavulanic Acids; Drug Evaluation; Drug Therapy, Combination; Endometritis; Female; Genital Diseases, Female; Humans; Pelvic Inflammatory Disease; Penicillins; Pregnancy; Ticarcillin

1990
Timentin therapy for bone, joint, and deep soft tissue infections in children.
    The American journal of medicine, 1985, Nov-29, Volume: 79, Issue:5B

    Timentin, a combination of clavulanic acid (0.1 g) and ticarcillin (3.0 g), has proved effective in vitro against bacterial pathogens that produce beta-lactamases. The usual etiologic bacteria of osteochondritis of the foot (Pseudomonas species) and osteomyelitis/septic arthritis (Staphylococcus aureus) are commonly resistant to penicillins. To date, we have used Timentin to treat 30 children with bone, joint, and deep soft tissue infections. Timentin was administered intravenously at an average dosage of 207 mg/kg per day for mild to moderate infection and 310 mg/kg per day for bone and joint infections with systemic signs (sepsis). The lower dose was used in 24 patients and the other six patients, who had signs of sepsis, received the higher dose. All patients received Timentin intravenously over 30 minutes every four to six hours for a minimum of five days (mean 6.6 +/- 2.6 days, range five to 14 days). The mean time to defervescence and/or reduction in clinical symptoms was 1.6 +/- 1.3 days (range zero to four days). Osteochondritis due to P. aeruginosa was diagnosed in six patients, and septic bursitis, osteomyelitis, or septic arthritis due to S. aureus (13 patients) or Staphylococcus species and group A streptococci (four patients) was diagnosed in 17 patients. All isolates were susceptible to Timentin in vitro by disk-diffusion analysis. All patients showed a response to therapy with Timentin, with or without surgical intervention. All patients had clinical and microbiologic cures; no adverse reactions or side effects were observed. There have been no clinical or microbiologic relapses to date. Timentin may prove to be useful in specific bone and joint infections in children.

    Topics: Arthritis, Infectious; Bacterial Infections; Bone Diseases; Cellulitis; Child; Child, Preschool; Clavulanic Acids; Drug Combinations; Female; Humans; Joint Diseases; Male; Osteochondritis; Osteomyelitis; Penicillins; Prospective Studies; Ticarcillin

1985